argenx to Speak at BofA Securities 2024 Health Care Conference

On May 7, 2024, argenx (Euronext & Nasdaq: ARGX), a global immunology company specializing in the treatment of severe autoimmune diseases, announced its upcoming participation in the BofA Securities 2024 Health Care Conference. This event is scheduled to take place on Tuesday, May 14, 2024, at 10:00 AM PT in Las Vegas, NV. The company's management team is set to engage in a fireside chat during the conference. Those interested can view the live webcast of the chat via the Investors section of the argenx website. Furthermore, a replay of the webcast will be accessible on the site for approximately 90 days post-event.

argenx is dedicated to enhancing the lives of individuals afflicted by severe autoimmune conditions. The company's strategy involves collaboration with top-tier academic researchers through its Immunology Innovation Program (IIP). This initiative aims to convert significant immunological discoveries into a premier collection of innovative antibody-based treatments. argenx has achieved a milestone by developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker across multiple countries including the U.S., Japan, Israel, the EU, the UK, Canada, and China.

The company is conducting extensive evaluations of efgartigimod, its pioneering drug, across a variety of serious autoimmune diseases. Additionally, argenx is advancing several early-stage experimental medications within its therapeutic franchises, continuously working toward expanding its impactful treatment portfolio.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!